Vivli’s Post

Many thanks to Daniel Levine for a great conversation on The Bio Report podcast about the many ways that #realworlddata can support evidence generation to benefit cancer patients, in particular recent approaches to enhancing trial representativeness by applying RWD to study design, and reducing patient and site burden by streamlining data collection needs. The closer we can integrate #clinicaltrials into routine care, the more likely that study results will be generalizable to ALL cancer patients.

The value of #RWD for informing better trial designs, supporting regulatory decisions, and improving patient diversity is critical as we continue to close the gap between care and research. Neal Meropol, Flatiron's Head of Research Oncology, was recently interviewed on The Bio Report with Daniel Levine to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development. Tune in to learn how Flatiron Health is harnessing the power of RWD to reshape the landscape of oncology research and accelerate the development of new treatments. ▶️ https://lnkd.in/g7YvHNK3

Learn now to access Integra Connect’s sample database in #SnowMarketplace to feature basic population-level statistics and visualizations that practices, payers and life science companies would use to assess a population of patients. https://okt.to/zSLpyM

On this #ClinicalTrialsDay, we commemorate Dr. James Lind's pioneering work on May 20, 1747, when he conducted the first-ever randomized controlled trial. Despite this milestone, we still have a long way to go in educating people about the importance and impact of clinical trials. #ClinicalResearch #HealthcareInnovation https://lnkd.in/givtHTTB #AYACSM #Tylenolstartedhere

With major advances in the understanding of cancer, the cancer treatment landscape has evolved, resulting in significant changes in therapy and in turn the primary endpoints elected for cancer clinical trials. Experts emphasize the need for transparency when changing primary endpoints in oncology clinical trials.

In Hungary, lung cancer is the leading cause of cancer death. While, since early 2022, molecular testing has been covered across the country, awareness about #precisionmedicine is still limited among healthcare professionals and patients. 🇭🇺The Hungary Country Pilot, a multi-stakeholder program led by Lélek-Zet to improve patient awareness of biomarker testing among patients with adapted materials, used the adaptable tool 𝗔𝗰𝗰𝗲𝘀𝘀 𝗕𝗮𝗿𝗿𝗶𝗲𝗿 𝗖𝗮𝘂𝘀𝗲-𝗘𝗳𝗳𝗲𝗰𝘁 𝗖𝗮𝗻𝘃𝗮𝘀 to map patients' needs. This resource is like a 𝗰𝗹𝗲𝗮𝗿 𝗽𝗶𝗰𝘁𝘂𝗿𝗲 of what patients experience, highlighting any roadblocks to accessing precision medicine. 👉 You can use it too! The tool is available for adaptation in your own practice or community: https://lnkd.in/dkp8K5iw

Want to see some #OHDSI OMOP Common Data Model in action? Check this out.

Did you know Inspire has helped researchers advance progress for more than 100 diseases? Inspire works with life sciences companies to provide real-world evidence and insights about the patient experience, connect patients with life-advancing clinical trials, and enable medical breakthroughs. What can Inspire help you discover? https://ow.ly/hGvc50Q7zW1 #RWE #RealWorldEvidence #PatientVoice #PatientExperience #PatientCentricity

Diversity in clinical trials - have you given any thoughts about your diversity plans? How exactly can you execute these plans? More importantly... where to even start? Fortrea offers a comprehensive and integrated "5-part process" solution for establishing, monitoring and reporting on Diversity Plan metrics in a clinical trials. Curious? Drop me a message! Or take a look at Joshua Richter's article - discusses the lack of diversity in clinical trials and how community oncologists can help overcome these disparities. #DiversityPlan #ClinicalTrials #oncology #diversity #Phase3

My article about Medical Tourism's misconceptions and risks published in HealthManagement. https://lnkd.in/d2XQ5-Ge Main Points -Medical Tourism data is usually provided by stakeholders, with a vested interest, varies widely, and should be viewed with a high degree of scepticism. -An ageing global population and a constantly growing middle class will increase the demand for healthcare services. However, this will not translate into exponential growth for the medical tourism sector. -Patients experience feelings such as stress, anxiety, depression, and grief that make them prefer to stay in familiar environments, close to home. -Healthcare is not a simple service but is viewed as a fundamental human right. When people are forced to travel abroad for medical services, this is considered a systemic failure and governments are criticised and pressured by local societies to develop an adequate healthcare system. -Influential interest groups will work against the idea of losing a significant portion of their clientele to foreign providers. -Although opportunities for investments in medical tourism exist in centres of excellence, niche markets, and specific geographical regions, healthcare is a local business and will remain so in the foreseeable future.